TCM
NUVB icon

Tanaka Capital Management’s Nuvation Bio NUVB Stock Holding History

Tanaka Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.87M Buy
901,825
+60,220
+7% +$335K 6.46% 6
2025
Q4 		$7.54M Buy
841,605
+156,500
+23% +$969K 13.76% 1
2025
Q3 		$2.54M Buy
+685,105
New +$1.87M 4.56% 6

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tanaka Capital Management's NUVB Position: Q1 2026 in Review

Tanaka Capital Management increased its Nuvation Bio (NUVB) stake by 7.2% in Q1 2026, buying an estimated $335K and bringing the position to 901,825 shares worth $3.87M. The position accounts for 6.46% of the portfolio, ranked #6.

Tanaka Capital Management first reported a position in NUVB in Q3 2025 and has held it in 3 quarters since. The position peaked at $7.54M in Q4 2025. 233 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Tanaka Capital Management held 901,825 shares of Nuvation Bio worth $3.87M as of Q1 2026.
  • Tanaka Capital Management bought 60,220 Nuvation Bio shares in Q1 2026, an estimated $335K.
  • Nuvation Bio made up 6.46% of Tanaka Capital Management's portfolio in Q1 2026, its #6 holding.
  • Tanaka Capital Management first reported a position in Nuvation Bio in Q3 2025 and has held it in 3 quarters since.
  • Tanaka Capital Management's Nuvation Bio position peaked at $7.54M in Q4 2025.
  • 233 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Tanaka Capital Management's 13F filing for Q1 2026, filed 18 May 2026.